"Medical fast reading society" cainge hepatitis C drug clopevir hydrochloride capsule approved

Novel coronavirus pneumonia was named as "COVID-19" by 24 at February 11th: 44653 cases were diagnosed by the national security organization; the only confirmed case in Tibet was cured and discharged; the Reed medicine was produced in Batai medicine, and the capsule of Kirin, clonavir hydrochloride, was approved As of 24:00 on February 11, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 38800 confirmed cases (8204 severe cases), 4740 cured and discharged cases, 1113 dead cases, 44653 confirmed cases and 16067 suspected cases (official website of National Health Commission) Novel coronavirus was officially named as the 2019 coronavirus disease, and the English acronym COVID-19 (Corona Virus Disease 2019) was announced by the director general of WHO, 11, on the day of the regular news briefing (World Health Organization) As of 22:30 on February 11, 925 patients had been admitted to the hospital Zhang sibing, the president of huoshenshan hospital, said the hospital will continue to treat patients on the 12th (Xinhua News Agency) The novel coronavirus pneumonia was confirmed in Tibet on the afternoon of 12 July It was completed by all the medical procedures and the third people's Hospital of Tibet autonomous region According to Hua Demi, director of the second Department of lung and head of the treatment group of the third people's Hospital of Tibet Autonomous Region, the first test result of the case was negative on February 9, and the re test result on February 11 is still negative At present, the clinical evidence including CT shows that the patient has recovered After discussion, the clinical group reported to the hospital and the health and Health Commission of Tibet Autonomous Region, and after evaluation by experts from the autonomous region and Shanghai Beijing, The case reached the standard of cure and discharge (people's daily) On the evening of November 11, Borui pharmaceutical announced that the company has successfully copied and developed the synthesis process technology and preparation technology of radcivir APIs, and has mass produced radcivir APIs, and the mass production of radcivir preparations is in progress (Sina Medical News) Recently, Geely announced the company's 2019 financial report revenue According to the financial report information, the company's total revenue in 2019 is 22.4 billion US dollars, an increase of 1.5% compared with 2018 Specifically in the product field, Geely's car-t therapy yescarta obtained through the acquisition of kite achieved sales performance of $456 million in 2019, achieving a 72.7% growth rate compared with the sales performance of $264 million in 2018, which is also one of the products with the highest growth rate of performance except for HIV drug biktarvy (medical Valley) On December 12, the State Food and Drug Administration announced that recently, the State Food and Drug Administration approved the listing of clopevir hydrochloride capsule (trade name: kailivi), a class 1 innovative drug of Beijing kaingeling Biotechnology Co., Ltd., through the priority review and approval procedure This product is used in combination with sophibuvir in the treatment of adult chronic hepatitis C virus (HCV) infection of gene 1, 2, 3 and 6, which is initially treated or treated with interferon It may or may not be combined with compensatory cirrhosis (Sina Medical News) China's biopharmaceutical company announced Thursday that its subsidiary company, Zhengda Tianqing, has obtained the Anda approval from the US FDA and the marketing license from the German Federal Drug and medical device administration (bfarm), respectively The drug is in the stage of applying for listing in China and is regarded as the application conformity evaluation (medicine cube) Pfizer announced Tuesday that the world's first oral preparation of transthyroxine protein stabilizer, vdaqel (20mg), was approved by China's National Drug Administration on February 5 for the treatment of adult patients with stage I symptoms of transthyroxine amyloidosis (attr-pn), in order to delay the damage of peripheral nerve function (Sina Medical News) On November 11, Novartis announced that the U.S FDA accepted the new drug application (NDA) of capmatinib (inc280), and granted priority review Capmatinib is an oral and selective met inhibitor Incyte authorized the research of the compound to Novartis in 2009 According to the agreement, Novartis obtained the global exclusive right to develop and commercialize all indications of capmatinib (Sina Medical News) Astaire and Pfizer recently published the final total survival (OS) analysis results of the phase III proser trial This study was carried out in patients with non metastatic castration resistant prostate cancer (nmcrpc) to evaluate the efficacy and safety of xtandi (enzalutamide) combined with androgen deprivation therapy (ADT) (Sina Medical News) Lilly recently announced that the European drug administration human pharmaceutical products committee has issued a positive review opinion, suggesting approval of the company's new meal insulin product, which can be used as part of the daily multiple injection program or delivered by insulin pump, for the treatment of adult diabetic patients (Biovalley)